中华肝胆外科杂志
中華肝膽外科雜誌
중화간담외과잡지
CHINESE JOURNAL OF HEPATOBILIARY SURGERY
2011年
6期
501-506
,共6页
张磊%赵文秀%尹震宇%苏维雪%周长升%王效民
張磊%趙文秀%尹震宇%囌維雪%週長升%王效民
장뢰%조문수%윤진우%소유설%주장승%왕효민
肝癌%肝星状细胞%免疫调节%微环境
肝癌%肝星狀細胞%免疫調節%微環境
간암%간성상세포%면역조절%미배경
Hepatocellular carcinoma%Hepatic stellate cells%Immune regulatory%Microenvironment
目的 研究活化的肝星状细胞(hepatic stellate cells,HSCs)在小鼠肝细胞癌发生发展中的免疫调节作用及肿瘤微环境的免疫功能变化.方法 于体外,用Brdu细胞增殖实验检测HSCs上清对肿瘤增殖的影响,用混合淋巴实验检测HSCs的免疫调节作用.体内实验采用皮下移植瘤模型,分为H22单纯注射组与H22+HSCs联合注射组.20 d后对荷瘤小鼠行瘤组织解剖测量移植瘤大小;用免疫组化法观察两组肿瘤中T细胞亚群浸润变化情况和接种肿瘤PD-L1的表达变化;用流式细胞术分析脾脏中T细胞亚群变化.然后,通过Tunel检测肿瘤组织单核细胞凋亡情况.结果 在体外实验,Brdu检测显示HSC:条件培养基(HSCs-CM)能明显诱导H22细胞的增殖,而混合淋巴实验则显示HSCs对T细胞增殖有明显的抑制作用.在体内实验,HSCs+H22组小鼠皮下移植瘤的形成时间与生长速度明显快于单纯接种H22组;肿瘤组织免疫组化检测显示HSCs+H22组浸润的T细胞及其亚型较单纯H22组有不同程度降低;HSCs+H22组脾脏亦显示T细胞及其亚型出现不同程度降低.TUNEL试剂盒检测显示HSCs+H22组肿瘤组织中单核细胞的凋亡数量增加,免疫组化分析显示HSCs+H22组肿瘤组织中PD-L1表达增加.结论 HSCs可通过免疫抑制作用在肿瘤微环境中促进肿瘤的发生、发展,这一发现可能为肝癌的治疗提供新的思路.
目的 研究活化的肝星狀細胞(hepatic stellate cells,HSCs)在小鼠肝細胞癌髮生髮展中的免疫調節作用及腫瘤微環境的免疫功能變化.方法 于體外,用Brdu細胞增殖實驗檢測HSCs上清對腫瘤增殖的影響,用混閤淋巴實驗檢測HSCs的免疫調節作用.體內實驗採用皮下移植瘤模型,分為H22單純註射組與H22+HSCs聯閤註射組.20 d後對荷瘤小鼠行瘤組織解剖測量移植瘤大小;用免疫組化法觀察兩組腫瘤中T細胞亞群浸潤變化情況和接種腫瘤PD-L1的錶達變化;用流式細胞術分析脾髒中T細胞亞群變化.然後,通過Tunel檢測腫瘤組織單覈細胞凋亡情況.結果 在體外實驗,Brdu檢測顯示HSC:條件培養基(HSCs-CM)能明顯誘導H22細胞的增殖,而混閤淋巴實驗則顯示HSCs對T細胞增殖有明顯的抑製作用.在體內實驗,HSCs+H22組小鼠皮下移植瘤的形成時間與生長速度明顯快于單純接種H22組;腫瘤組織免疫組化檢測顯示HSCs+H22組浸潤的T細胞及其亞型較單純H22組有不同程度降低;HSCs+H22組脾髒亦顯示T細胞及其亞型齣現不同程度降低.TUNEL試劑盒檢測顯示HSCs+H22組腫瘤組織中單覈細胞的凋亡數量增加,免疫組化分析顯示HSCs+H22組腫瘤組織中PD-L1錶達增加.結論 HSCs可通過免疫抑製作用在腫瘤微環境中促進腫瘤的髮生、髮展,這一髮現可能為肝癌的治療提供新的思路.
목적 연구활화적간성상세포(hepatic stellate cells,HSCs)재소서간세포암발생발전중적면역조절작용급종류미배경적면역공능변화.방법 우체외,용Brdu세포증식실험검측HSCs상청대종류증식적영향,용혼합림파실험검측HSCs적면역조절작용.체내실험채용피하이식류모형,분위H22단순주사조여H22+HSCs연합주사조.20 d후대하류소서행류조직해부측량이식류대소;용면역조화법관찰량조종류중T세포아군침윤변화정황화접충종류PD-L1적표체변화;용류식세포술분석비장중T세포아군변화.연후,통과Tunel검측종류조직단핵세포조망정황.결과 재체외실험,Brdu검측현시HSC:조건배양기(HSCs-CM)능명현유도H22세포적증식,이혼합림파실험칙현시HSCs대T세포증식유명현적억제작용.재체내실험,HSCs+H22조소서피하이식류적형성시간여생장속도명현쾌우단순접충H22조;종류조직면역조화검측현시HSCs+H22조침윤적T세포급기아형교단순H22조유불동정도강저;HSCs+H22조비장역현시T세포급기아형출현불동정도강저.TUNEL시제합검측현시HSCs+H22조종류조직중단핵세포적조망수량증가,면역조화분석현시HSCs+H22조종류조직중PD-L1표체증가.결론 HSCs가통과면역억제작용재종류미배경중촉진종류적발생、발전,저일발현가능위간암적치료제공신적사로.
Objective To determine immune modulatory activity of activated hepatic stellate cells( HSCs) in hepatocellular carcinoma and immune response in tumor microenvironment. Methods Cell proliferation was measured by BrdU incorporation with a microtiter plate reader at 450 nm. The effect of HSCs on T cell proliferation was measured by MLR. Mouse hepatic cancer cell line H22 were implanted on the backs of BALB/c mice to establish the subcutaneous transplanted tumor model. Then the mice were sacrificed after 20 days for anatomical and size determination. Furthermore, Paraffin-embedded tissue was removed by serial tissue sectioning and immunohistochemically examined for expression of T lymphocyte subsets. T lymphocyte subsets in splenocytes were detected by FCM. Apoptotic mononuclear cells were evaluated by FITC-labeled Tunel assay. Results We determined that HSCsCM promoted hepatocellular carcinoma(HCC) cell line proliferation and HSCs inhibit T cell proliferation by MLR in vitro. We also examined normal immune mice to assess the immunosuppression of HSCs in the development of HCC. In the co-transplantation with HSCs group, T cells and their subtypes decreased obviously in the tumors and the spleen. The results showed that co-transplanted HSCs can induce more PD-L1 expression and more mononuclear cell apoptosis in tumor tissue. Conclusion Our results demonstrated that HSCs promote HCC progression partially because of their immune regulatory activity. Our data supply new information to support an integral role for HSCs in promoting HCC progression and suggest that HSCs may serve as a therapeutic target for HCC.